ProPhase Labs, Inc. Proceeds from Sale and Maturity of Marketable Securities
ProPhase Labs, Inc. (PRPH) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2025-11-19
- ProPhase Labs, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $0.00.
- ProPhase Labs, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-06-30 was $0.00.
- ProPhase Labs, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2024-12-31 was -$3.37M.
- ProPhase Labs, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ProPhase Labs, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $3.82M, a 264.57% increase from fiscal 2022.
- ProPhase Labs, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $1.05M, a 93.40% decline from fiscal 2021.
- ProPhase Labs, Inc. proceeds from sale and maturity of marketable securities for fiscal 2021 was $15.86M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2025-11-19 | $0.00 10-Q · filed 2025-11-19 | -$3.37M derived: sum of 4 quarters · filed 2025-11-19 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | -$3.37M derived: sum of 3 quarters · filed 2025-08-13 | -$3.37M derived: sum of 4 quarters · filed 2025-11-19 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-20 | -$3.37M derived: sum of 2 quarters · filed 2025-05-20 | -$3.37M derived: sum of 3 quarters · filed 2025-11-19 | -$3.37M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-12-31 | -$3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | -$3.37M derived: sum of 2 quarters · filed 2025-11-19 | -$3.37M derived: sum of 3 quarters · filed 2025-11-19 | $0.00 10-K · filed 2025-04-01 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2025-11-19 | $3.37M 10-Q · filed 2025-11-19 | $3.37M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.37M 10-Q · filed 2025-08-13 | $3.37M derived: sum of 3 quarters · filed 2025-08-13 | $4.37M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $3.37M 10-Q · filed 2025-05-20 | $3.37M derived: sum of 2 quarters · filed 2025-05-20 | $4.37M derived: sum of 3 quarters · filed 2025-05-20 | $5.90M derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $1.00M derived: sum of 2 quarters · filed 2025-04-01 | $2.53M derived: sum of 3 quarters · filed 2025-04-01 | $3.82M 10-K · filed 2025-04-01 |
| 2023-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.53M derived: sum of 2 quarters · filed 2024-11-13 | $3.82M 10-Q · filed 2024-11-13 | -$936.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.82M 10-Q · filed 2024-08-14 | -$1.94M derived: sum of 3 quarters · filed 2024-08-14 | $3.86M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.29M 10-Q · filed 2024-05-10 | -$3.46M derived: sum of 2 quarters · filed 2024-05-10 | $2.34M derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | -$4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.05M derived: sum of 2 quarters · filed 2024-03-29 | $1.05M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $5.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $5.80M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-11 | |||
| 2021-12-31 | $15.86M 10-K · filed 2023-03-29 | |||
| 2019-12-31 | $4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $5.59M derived: sum of 2 quarters · filed 2020-03-26 | $6.44M derived: sum of 3 quarters · filed 2020-03-26 | $8.91M 10-K · filed 2020-03-26 |
| 2019-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $1.87M derived: sum of 2 quarters · filed 2019-11-12 | $4.34M 10-Q · filed 2019-11-12 | $5.84M derived: sum of 4 quarters · filed 2020-03-26 |
| 2019-06-30 | $849.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $3.32M 10-Q · filed 2019-08-12 | $4.82M derived: sum of 3 quarters · filed 2020-03-26 | $4.82M derived: sum of 4 quarters · filed 2020-03-26 |
| 2019-03-31 | $2.47M 10-Q · filed 2019-05-14 | $3.97M derived: sum of 2 quarters · filed 2020-03-26 | $3.97M derived: sum of 3 quarters · filed 2020-03-26 | $13.09M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $1.50M derived: sum of 2 quarters · filed 2020-03-26 | $10.62M derived: sum of 3 quarters · filed 2020-03-26 | $11.07M 10-K · filed 2020-03-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $9.12M derived: sum of 2 quarters · filed 2019-11-12 | $9.57M 10-Q · filed 2019-11-12 | $13.91M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $9.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $9.57M 10-Q · filed 2019-08-12 | $13.91M derived: sum of 3 quarters · filed 2019-08-12 | |
| 2018-03-31 | $450.00K 10-Q · filed 2019-05-14 | $4.78M derived: sum of 2 quarters · filed 2019-05-14 | ||
| 2017-12-31 | $4.33M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2018-08-20 | $12.85M 10-K/A · filed 2018-08-20 | ||
| 2017-09-30 | $8.52M 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |